Central Hospital of Linyi City , Yishui, Shandong, China.
Expert Rev Clin Immunol. 2020 Aug;16(8):739-743. doi: 10.1080/1744666X.2020.1801421. Epub 2020 Aug 9.
Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which indicated for treating thyroid eye disease.
The authors performed a systematic review of the literature using the PubMed database, and the following keywords were used: 'teprotumumab,' 'thyroid eye disease,' and 'insulin-like growth factor I receptor.' The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of teprotumumab were introduced in this paper.
Teprotumumab is a human monoclonal antibody targeting insulin-like growth factor-I receptor. Clinical trials indicated that proptosis response of teprotumumab was 83%, and clinical activity score, diplopia, and quality of life were also better than placebo. Teprotumumab was well tolerated, common adverse reactions included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.
甲状腺眼病是一种使人衰弱、毁容且可能致盲的眼周疾病。特普罗鲁单抗是一种人胰岛素样生长因子-I 受体单克隆抑制剂抗体，用于治疗甲状腺眼病。
作者使用 PubMed 数据库进行了系统的文献回顾，并使用了以下关键词：“特普鲁单抗”、“甲状腺眼病”和“胰岛素样生长因子 I 受体”。本文介绍了特普鲁单抗的化学性质、作用机制、药代动力学、临床疗效和安全性。
特普鲁单抗是人胰岛素样生长因子-I 受体的单克隆抗体。临床试验表明，特普鲁单抗的眼球突出反应为 83%，临床活动评分、复视和生活质量也优于安慰剂。特普鲁单抗耐受性良好，常见不良反应包括肌肉痉挛、恶心、脱发、腹泻、疲劳、高血糖、听力障碍、味觉障碍、头痛和皮肤干燥。
